You have no items in your shopping cart.
Description
Research Area
Images & Validation
−| Tested Applications | ELISA, IHC-P, WB |
|---|---|
| Dilution Range | IHC-P: 1:50-300 (based on 0.5mg/ml), WB: 1:100-500 |
| Reactivity | Human, Mouse, Rat |
Key Properties
−| Host | Rabbit |
|---|---|
| Clonality | Polyclonal |
| Isotype | IgG |
| Immunogen | KLH conjugated synthetic peptide derived from human CD274. Please contact us for the exact immunogen sequence. The peptide is available as orb374702. |
| Target | CD274 |
| Molecular Weight | 33 kDa |
| Purity | Polyclonal antibodies are purified by peptide affinity chromatography |
| Conjugation | Unconjugated |
Storage & Handling
−| Storage | Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
|---|---|
| Form/Appearance | 10 mM PBS, 0.02% sodium azide |
| Concentration | - 100 μg (in 200 μl): 0.5 mg/ml- 200 μg (in 400 μl): 0.5 mg/ml |
| Expiration Date | 12 months from date of receipt. |
| Disclaimer | For research use only |
Alternative Names
−Similar Products
−PD-L1 Monoclonal Antibody [orb688863]
ELISA, FC, IF, IHC, WB
Human
Mouse
Monoclonal
Unconjugated
50 μl, 100 μlPD-L1 Antibody / B7-H1 / CD274 [orb606675]
ELISA, FACS, IF, IHC-P, WB
Human
Mouse
Monoclonal
Unconjugated
20 μgPD-L1 Antibody / B7-H1 / CD274 [orb2641417]
ELISA, FACS, IF, IHC-P, WB
Human
Mouse
Monoclonal
Unconjugated
100 μgPD-L1 Monoclonal Antibody [orb688864]
ELISA, FC, IF, IHC, WB
Human
Mouse
Monoclonal
Unconjugated
50 μl, 100 μl

Quality Guarantee
Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].
Protocol Information
Hubert, Pascale et al. Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy J Immunother Cancer, 9, (2021)





















































![Anti-PDL1 [YDC 127.1.1]](/images/pub/media/catalog/product/NewWebsite/35/orb613832_1.png)
![Anti-PDL1 [YDC 127.1.1]](/images/pub/media/catalog/product/NewWebsite/35/orb613832_2.png)
![Anti-PDL1 [YDC 127.1.1]](/images/pub/media/catalog/product/NewWebsite/35/orb613832_3.png)
![Anti-PDL1 [YDC 127.1.1]](/images/pub/media/catalog/product/NewWebsite/35/orb613832_4.png)
![Anti-PDL1 [YDC 127.1.1]](/images/pub/media/catalog/product/NewWebsite/35/orb613832_5.png)